DOCSLIB.ORG

205777Orig1s000

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
205777Orig1s000 CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 205777Orig1s000 MEDICAL REVIEW(S) CLINICAL REVIEW Application Type NDA Application Number(s) 205-777 Priority or Standard Standard Submit Date(s) September 23, 2013 Received Date(s) September 23, 2013 PDUFA Goal Date July 23, 2014 Division / Office Anesthesia, Analgesia and Addiction Products (DAAAP) Reviewer Name(s) Elizabeth Kilgore, MD Review Completion Date June 18, 2014 Established Name Oxycodone/Naloxone (Proposed) Trade Name Targiniq ER Therapeutic Class Combination Opioid Analgesic and Opioid Antagonist (Abuse Deterrent Formulation) Applicant Purdue Pharma L.P. Formulation(s) Oral tablet Dosing Regimen Every 12 hours Indication(s) Management of pain severe enough to require daily, around- the-clock, long-term opioid treatment and for which alternative treatment options are inadequate Intended Population(s) Adults aged ≥18 years Template Version: March 6, 2009 Reference ID: 3527578 Clinical Review Elizabeth Kilgore, MD NDA 205-777 Targiniq ER (Oxycodone/Naloxone) Table of Contents 1 RECOMMENDATIONS/RISK BENEFIT ASSESSMENT ......................................... 8 1.1 Recommendation on Regulatory Action ............................................................. 8 1.2 Risk Benefit Assessment .................................................................................... 9 1.3 Recommendations for Postmarket Risk Evaluation and Mitigation Strategies . 10 1.4 Recommendations for Postmarket Requirements and Commitments .............. 10 2 INTRODUCTION AND REGULATORY BACKGROUND ...................................... 10 2.1 Product Information .......................................................................................... 10 2.2 Tables of Currently Available Treatments for Proposed Indications ................. 11 2.3 Availability of Proposed Active Ingredient in the United States ........................ 11 2.4 Important Safety Issues With Consideration to Related Drugs ......................... 12 2.5 Summary of Presubmission Regulatory Activity Related to Submission .......... 12 2.6 Other Relevant Background Information .......................................................... 13 3 ETHICS AND GOOD CLINICAL PRACTICES ....................................................... 14 3.1 Submission Quality and Integrity ...................................................................... 14 3.2 Compliance with Good Clinical Practice ........................................................... 14 3.3 Financial Disclosures ........................................................................................ 15 4 SIGNIFICANT EFFICACY/SAFETY ISSUES RELATED TO OTHER REVIEW DISCIPLINES ......................................................................................................... 15 4.1 Chemistry Manufacturing and Controls ............................................................ 15 4.2 Clinical Microbiology ......................................................................................... 16 4.3 Preclinical Pharmacology/Toxicology ............................................................... 16 4.4 Clinical Pharmacology ...................................................................................... 17 4.4.1 Mechanism of Action .................................................................................. 17 4.4.2 Pharmacodynamics.................................................................................... 17 4.4.3 Pharmacokinetics ....................................................................................... 18 5 SOURCES OF CLINICAL DATA............................................................................ 19 6 REVIEW OF EFFICACY ......................................................................................... 46 6.1.10 Additional Efficacy Issues/Analyses ........................................................... 59 7 REVIEW OF SAFETY ............................................................................................. 59 Safety Summary ........................................................................................................ 59 7.1 Methods ............................................................................................................ 60 7.1.1 Studies/Clinical Trials Used to Evaluate Safety ......................................... 60 7.1.2 Categorization of Adverse Events .............................................................. 60 7.1.3 Pooling of Data Across Studies/Clinical Trials to Estimate and Compare Incidence .................................................................................................... 60 7.2 Adequacy of Safety Assessments .................................................................... 62 2 Reference ID: 3527578 Clinical Review Elizabeth Kilgore, MD NDA 205-777 Targiniq ER (Oxycodone/Naloxone) 7.2.1 Overall Exposure at Appropriate Doses/Durations and Demographics of Target Populations ..................................................................................... 62 7.2.2 Explorations for Dose Response ................................................................ 66 7.2.3 Special Animal and/or In Vitro Testing ....................................................... 69 7.2.4 Routine Clinical Testing ............................................................................. 70 7.2.5 Metabolic, Clearance, and Interaction Workup .......................................... 70 7.2.6 Evaluation for Potential Adverse Events for Similar Drugs in Drug Class .. 70 7.3 Major Safety Results ........................................................................................ 70 7.3.4 Significant Adverse Events ........................................................................ 87 7.3.5 Submission Specific Primary Safety Concerns .......................................... 89 7.4 Supportive Safety Results .............................................................................. 102 7.4.1 Common Adverse Events ........................................................................ 102 7.4.2 Laboratory Findings ................................................................................. 104 7.4.3 Vital Signs ................................................................................................ 104 7.4.4 Electrocardiograms (ECGs) ..................................................................... 105 7.4.5 Special Safety Studies/Clinical Trials ....................................................... 105 7.4.6 Immunogenicity ........................................................................................ 107 7.5 Other Safety Explorations ............................................................................... 107 7.5.1 Dose Dependency for Adverse Events .................................................... 107 7.5.2 Time Dependency for Adverse Events ..................................................... 109 7.5.3 Drug-Demographic Interactions ............................................................... 110 7.5.4 Drug-Disease Interactions ........................................................................ 110 7.5.5 Drug-Drug Interactions ............................................................................. 111 7.6 Additional Safety Evaluations ......................................................................... 111 7.6.1 Human Carcinogenicity ............................................................................ 111 7.6.2 Human Reproduction and Pregnancy Data .............................................. 111 7.6.3 Pediatrics and Assessment of Effects on Growth .................................... 111 7.6.4 Overdose, Drug Abuse Potential, Withdrawal and Rebound .................... 112 7.7 Additional Submissions / Safety Issues .......................................................... 114 8 POSTMARKET EXPERIENCE ............................................................................. 114 9 APPENDICES ...................................................................................................... 118 9.1 Literature Review/References ........................................................................ 118 9.2 Labeling Recommendations ........................................................................... 118 9.3 Advisory Committee Meeting .......................................................................... 119 CLINICAL INVESTIGATOR FINANCIAL DISCLOSURE FORM ............................... 130 3 Reference ID: 3527578 Clinical Review Elizabeth Kilgore, MD NDA 205-777 Targiniq ER (Oxycodone/Naloxone) Table of Tables Table 1. Brand Name Naloxone Products and Indications ........................................... 12 Table 2. Pharmacokinetic Parameters for Oxycodone (Mean [SD]) ............................. 18 Table 3. Pharmacokinetic Parameters for Naloxone (Mean [SD]) ................................ 18 Table 4. Clinical Studies in Pooled Safety Database.................................................... 21 Table 5. Schedule of Visits and Procedures Protocol ONU3701 .................................. 34 Table 6. Blinded Taper for Subjects Randomized to Matching Placebo ....................... 38 Table 7. Amendments to Protocol ................................................................................ 41 Table 8. Primary and Supportive Efficacy Studies ....................................................... 43 Table 9. Phase 1 Studies Key Characteristics ............................................................. 45
Load more

Recommended publications
  • ESTIMATED WORLD REQUIREMENTS of NARCOTIC DRUGS in GRAMS for 2019 (As of 10 January 2019 )
    ESTIMATED WORLD REQUIREMENTS OF NARCOTIC DRUGS IN GRAMS FOR 2019 (as of 10 January 2019 ) Afghanistan Cannabis 50 Codeine 50 000 Cannabis resin 1 Dextropropoxyphene 10 000 Coca leaf 1 Diphenoxylate 5 000 Cocaine 15 Fentanyl 1 Codeine 650 000 Methadone 20 000 Codeine -N-oxide 1 Morphine 8 000 Dextromoramide 1 Pethidine 90 000 Dextropropoxyphene 200 000 Pholcodine 40 000 Difenoxin 1 Albania Dihydrocodeine 1 Cocaine 1 Diphenoxylate 1 Codeine 1 189 000 Dipipanone 1 Fentanyl 300 Ecgonine 2 Heroin 1 Ethylmorphine 1 Methadone 7 000 Etorphine 1 Morphine 7 800 Fentanyl 17 000 Oxycodone 2 000 Heroin 1 Pethidine 2 700 Hydrocodone 10 000 Pholcodine 1 500 Hydromorphone 4 000 Remifentanil 9 Ketobemidone 1 Sufentanil 2 Levorphanol 1 Algeria Methadone 100 000 Alfentanil 350 Morphine 1 550 000 Codeine 2 500 000 Morphine -N-oxide 1 Etorphine 1 Nicomorphine 1 Fentanyl 500 Norcodeine 1 Methadone 4 000 Normethadone 1 Morphine 9 000 Normorphine 1 Oxycodone 4 000 Opium 10 Pethidine 3 000 Oripavine 1 Pholcodine 1 500 000 Oxycodone 60 000 Remifentanil 1 Oxymorphone 1 Sufentanil 30 Pethidine 50 000 Andorra Phenoperidine 1 Cannabis 2 000 Pholcodine 1 Fentanyl 100 Piritramide 1 Methadone 1 000 Remifentanil 20 000 Morphine 500 Sufentanil 10 Oxycodone 2 000 Thebacon 1 Pethidine 500 Thebaine 70 000 Remifentanil 4 Tilidine 1 Angola Armenia Alfentanil 20 Codeine 3 000 Codeine 21 600 Fentanyl 40 Dextromoramide 188 Methadone 13 500 Dextropropoxyphene 200 Morphine 7 500 Dihydrocodeine 500 Thebaine 15 Diphenoxylate 300 Trimeperidine 1 500 Fentanyl 63 Aruba* Methadone 2 000
    [Show full text]
  • Problems of Drug Dependence 1980 Proceedings of the 42Nd Annual Scientific Meeting the Committee on Problems of Drug Dependence
    National Institute on Drug Abuse MONOGRAPH SERIES Problems of Drug Dependence 1980 Proceedings of the 42nd Annual Scientific Meeting The Committee on Problems of Drug Dependence, Inc. U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES • Public Health Service • Alcohol, Drug Abuse, and Mental Health Administration Problems of Drug Dependence, 1980 Proceedings of the 42nd Annual Scientific Meeting, The Committee on Problems of Drug Dependence, Inc. Editor: Louis S. Harris, Ph.D. NIDA Research Monograph 34 February 1981 DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Alcohol, Drug Abuse, and Mental Health Administration National Institute on Drug Abuse Division of Research 5600 Fishers Lane Rockville, Maryland 20857 For sale by the Superintendent of Documents, U.S. Government Printing Office Washington, D.C. 20402 The NIDA Research Monograph series is prepared by the Division of Research of the National Institute on Drug Abuse. Its primary objective is to provide critical reviews of research problem areas and techniques, the content of state-of-the-art conferences, integrative research reviews and significant original research. Its dual publication emphasis is rapid and targeted dissemination to the scientific and professional community. Editorial Advisory Board Avram Goldstein, M.D. Addiction Research Foundation Palo Alto, California Jerome Jaffe, M.D. College of Physicians and Surgeons Columbia University, New York Reese T. Jones, M.D. Langley Porter Neuropsychiatric Institute University of California San Francisco, California William McGlothlin, Ph.D. Deportment of Psychology, UCLA Los Angeles, California Jack Mendelson, M.D. Alcohol and Drug Abuse Research Center Harvard Medical School McLean Hospital Belmont, Massachusetts Helen Nowlis, Ph.D. Office of Drug Education, DHHS Washington, D.C Lee Robins, Ph.D.
    [Show full text]
  • Quality Issues in Caring for Older People
    Doctoral Thesis - Tesis Doctoral Quality issues in caring for older people: • Appropriateness of transition from long-term care facilities to acute hospital care • Potentially inappropriate medication: development of a European list Anna Renom Guiteras Prof. Gabriele Meyer Prof. Ramón Miralles Basseda Martin Luther University Halle-Wittenberg Universitat Autònoma de Barcelona Halle (Saale) & Barcelona, Catalonia University of Witten/Herdecke Spain Witten Germany Programa de doctorat en Medicina Departament de Medicina, Facultat de Medicina Universitat Autònoma de Barcelona Barcelona, 2015 13 Contents 15 1. Introduction • Research context • Background of the research topics • Pesetaio of the ailes 23 2. Summary and discussion of the results 31 3. Conclusions 37 4. References 47 5. Articles • Article 1: Renom-Guiteras A, Uhrenfeldt L, Meyer G, Mann E. Assessment tools for determining appropriateness of admission to acute care of persons transferred from long-term care facilities: a systematic review. BMC Geriatr. 2014;14:80 • Article 2: Renom-Guiteras A, Meyer G, Thürmann PA. The EU(7)-PIM list: a list of potentially inappropriate medications for older people consented by experts from seven European countries. Eur J Clin Pharmacol. 2015;71(7):861-75 77 6. Annexes • Annex 1.1 (article 1) - Additional file 1: Studies dealing with assessment tools for determining appropriateness of hospital admissions among residents of LTC facilities. • Annex 1.2 (article 1) - Additional file 2: Characteristics of the assessment tools for determining appropriateness of hospital admissions among residents of LTC facilities. • Annex 2.1 (article 2) - Appendix 1: Complete EU(7)-PIM list • Annex 2.2 (article 2) - Appendix 2: Questionable Potentially Inappropriate Medications (Questionable PIM): results of the Delphi survey.
    [Show full text]
  • Misuse and Abuse of Opioid Analgesics – the Role of the Internet
    Misuse and Abuse of Opioid Analgesics – the Role of the Internet H. Siemann, J. Schnell, N. Scherbaum LVR Hospital Essen, Clinic for Dependent Behavior and Addiction Medicine University of Duisburg-Essen, Germany Misuse and Abuse of Opioid Analgesics – the Role of the Internet 09/18/2009 Opioid Analgesics • Prescription Drugs – Tramadol, Tilidine, Codeine, Loperamide – Easy to prescribe • Schedule III Drugs according to the German Narcotics Act (BtmG) – Morphine, Methadone, Fentanyl, Buprenorphine, Oxycodone – Special conditions to be fulfilled for a valid presciption Holger Siemann ([email protected]) 2 Misuse and Abuse of Opioid Analgesics – the Role of the Internet 09/18/2009 Prescription Rate Holger Siemann ([email protected]) 3 Misuse and Abuse of Opioid Analgesics – the Role of the Internet 09/18/2009 Non-Scheduled Opioids • Tramadol – Pain management (post-surgery treatment, injury treatment) • Tilidine + Naloxone (Valoron N®) – Higher analgesic potency – Prevention of parenteral drug abuse by combination with the µ-receptor antagonist Naloxone Holger Siemann ([email protected]) 4 Misuse and Abuse of Opioid Analgesics – the Role of the Internet 09/18/2009 Aim of the Study • To assess the role of the internet regarding the abuse of prescription opioids – Role as a trading platform – Role as an information system Holger Siemann ([email protected]) 5 Misuse and Abuse of Opioid Analgesics – the Role of the Internet 09/18/2009 Methods • Analysis of the first 50 websites provided by the leading search engine Google for
    [Show full text]
  • Narcotic Drugs Stupefiants Estupefacientes
    E/INCB/1993/21Supp.6 INTERNATIONAL NARCOTICS CONTROL BOARD - VIENNA SUPPLEMENT No. 6 TO NARCOTIC DRUGS ESTIMATED WORLD REQUIREMENTS FOR 1994 STATISTICS FOR 1992 ESTIMATES UPDATED AS OF 30 JUNE 1994 ORGANE INTERNATIONAL DE CONTROLE DES STUPEFIANTS - VIENNE SUPPLEMENT N° 6 A r STUPEFIANTS EVALUATIONS DES BESOINS DU MONDE POUR 1994 STATISTIQUES POUR 1992 EVALUATIONS A JOUR AU 30 JUlN 1994 JUNTA INTERNACIONAL DE FISCALlZACION DE ESTUPEFACIENTES - VIENA SUPLEMENTO N.o 6 A ESTUPEFACIENTES PREVISIONES DE LAS NECESIDADES MUNDIALES PARA 1994 ESTADfsTICAS PARA 1992 PREVISIONES ACTUALlZADAS AL 30 DE JUNIO DE 1994 ~If..~~ ~ ~-tR UNITED NATIONS - NATIONS UNIES - NACIONES UNIDAS 1994 The updating of Table A is carried out by means of 12 monthly supplements. In order to facilitate the task of the exporting countries, the 12 supplements now report all the totals of the estimates and not only the amended data. In this way, each supplement cancels and replaces the published table in its entirety. In order to accelerate the transmission of the supplements to the competent national authorities, the 12 supplements will appear in English. Reading of these 12 supplements in French and Spanish may be facilitated by consulting the indexes of countries and territories and of narcotic drugs appearing in the annual publication. La mise El jour du tableau A s'effectue au moyen de douze supplements mensuels. Afin de faciliter la tache des pays exportateurs, les douze supplements contiennent tous les totaux des evaluations et non pas seulement les chiffres qui ont ete modifies. De celte maniere, chaque supplement annule et remplace entierement le tableau publie.
    [Show full text]
  • 0 Cover Part Two\374
    PART TWO DEUXIÈME PARTIE SEGUNDA PARTE ﺍﳉﺰﺀ ﺍﻟﺜﺎﱐ 第二部分 ЧАСТЬ ВТΟΡАЯ - (...), [...] - (-)-3-hidroxi-N- (-)-(2R)-N-méthyl-1- fenacilmorfinán → Levophenacyl-morphan phénylpropan-2-amine → Levometamfetamine (-)-3-hidroxi-N- (-)-(3S,6R)-6- metilmorfinán → Levorphanol (dimethylamino)-4,4- (-)-3-hydroksymorfinan → Norlevorphanol diphenyl-3-heptanol → Betamethadol (-)-3-hydroksy-N- (-)-(3S,6R)-6- fenacylmorfinan → Levophenacyl-morphan (dimethylamino)-4,4- (-)-3-hydroksy-N- diphenyl-3-heptanol metylmorfinan → Levorphanol acetate (ester) → Betacetylmethadol (-)-3-hydroxymorphinan → Norlevorphanol (-)-(5R)-4,5-epoxy-3- (-)-3-hydroxy-N- methoxy-9α-methyl methylmorphinan → Levorphanol → Thebacon morphin-6-en-6-yl acetate (-)-3-hydroxynormorphinan → Norlevorphanol (-)-(5R,6S)-3-benzyloxy-4,5- (-)-3-hydroxy-N- epoxy-9a-methylmorphin- phenacylmorphinan → Levophenacyl-morphan 7-en-6-yl myristate → Myrophine (-)-3-hydroxytropane-2- (-)-(5R,6S)-4,5-epoxy carboxylat → Ecgonine morphin-7-en-3,6-diol → Normorphine (-)-3-idrossi-N- (-)-(5R,6S,14S)-4,5-epoxy- metilmorfinano → Levorphanol 14-hydroxy-3-methoxy- (-)-3-methoxy-N- 9a-methylmorphinan-6- methylmorphinan → Levomethorphan one → Oxycodone (-)-3-metil-2,2-difenil-4- (-)-(R)-4,5-epoxy-3- morfolinbutirilpirrolidina → Levomoramide methoxy-9a-methyl (-)-3-metoksy-N- morphinan-6-one → Hydrocodone metylmorfinan → Levomethorphan (-)-(R)-6-(dimethylamino)- (-)-3-metossi-N-metil- 4,4-diphenyl-3-heptanone → l-methadone morfinano → Levomethorphan (-)-(R)-N,α-dimethyl (-)-3-metoxi-N- phenethylamine → Levometamfetamine
    [Show full text]
  • List of Participants ...8
    WORLD HEALTH ORGANIZATION ORGANISATION MONDIALE DE LA SANTI? ENGLISH ONLY REVIEW OF PSYCHOACTIVE SUBSTANCES FOR INTERNATIONAL CONTROL 26-28 SEPTEMBER 1979 CONTENTS Page Introduction ........................................ 2 Scope of the meeting ......................................... 2 Review of drugs for International Control........,........... 3 Sufentanil ................................................. 3 Tilidine..................................................... 3 Dextropropoxyphene .......................................... 4 Phencyclidine ................................................ 4 Phencyclidine analogues ...................................... 5 Mecloqualone ................................................ 5 Selection of further substances requiring control.. .. , . 6 The need for more and better information.. .. .. .. .. 6 List of participants ....................................... 8 List of background documents.. ............................... 10 Annex 1: Summary of the discussion on Investigation of the Stimulant and Reinforcing Properties of Self-Administration of Phenylethylamine Derivatives isolated from Catha.ed. (Khat).. 11-14 e issue of this document does not constitute Ce document ne constitue pas une publication. al publication. It should not be reviewed, II ne doit faire I'objet d'aucun cornpte rendu ou racted or quoted without the agreement of rdsumb ni d'aucune citation sans I'autorisation de e World Health Organization. Authors alone I'Organisation Mondiale de la Sant6. Les opinions responsible for
    [Show full text]
  • Use of Chronic Opioid Therapy in Chronic Noncancer Pain CHRONIC NONCANCER PAINNONCANCER CHRONIC Evidence Review
    CLINICAL GUIDELINE FOR THE USE OF CHRONIC OPIOID THERAPY IN CLINICAL GUIDELINE FOR THE USE OF CHRONIC OPIOID THERAPY IN GUIDELINE FOR THE Use of Chronic Opioid Therapy in Chronic Noncancer Pain CHRONIC NONCANCER PAIN Evidence Review The American Pain Society in Conjunction with The American Academy of Pain Medicine EVIDENCE REVIEW APS-AAPM Clinical Guidelines for the Use of Chronic Opioid Therapy in Chronic Noncancer Pain TABLE OF CONTENTS Page Introduction 1 Purpose of evidence review ...................................................................... 1 Background 1 Previous guidelines ................................................................................... 2 Scope of evidence review 3 Key questions............................................................................................ 3 Populations................................................................................................ 7 Interventions.............................................................................................. 8 Outcomes.................................................................................................. 8 Conflict of interest............................................................................................. 10 Methods 10 Literature search and strategy................................................................... 10 Inclusion and exclusion criteria.................................................................. 11 Data extraction and synthesis ..................................................................
    [Show full text]
  • Narcotic Drugs — Estimated World Requirements for 2018
    English — Comments COMMENTS ON THE REPORTED STATISTICS ON NARCOTIC DRUGS Part two Part Summary The further overall reduction in global stocks and in the production of opium confirm the con- Deuxi tinuing trend towards the eventual elimination of the drug from the international market for è opiate raw material. me partie Poppy straw and concentrate of poppy straw derived from the two main varieties of poppy straw (the morphine-rich and thebaine-rich varieties) decreased slightly in 2016 compared Segunda parte with 2015, and the manufacture of morphine remained stable at 422.1 tons, of which around 87 per cent of global manufacture was converted into other narcotic drugs or into substances not covered by the 1961 Convention. Of the remaining 13 per cent, only 8.6 per cent was directly consumed for palliative purposes. The differences in consumption levels between countries continued to be very significant. In 2016, 80 per cent of the world population consumed only 14 per cent of the total amount of morphine used for the management of pain and suffering. Although that represented an improvement on 2014, when 80 per cent of the world population consumed 9.5 per cent, the disparity in consumption of narcotic drugs for palliative care continues to be a matter of concern. After some fluctuations in the preceding years, global manufacture of thebaine reached the record level of 156 tons in 2016, signalling that the demand for medicines derived from thebaine, after having decreased in the past several years, appears to have resumed, despite restrictions on prescription drugs recently imposed in the main market (the United States of America) in response to their abuse and the high number of overdose deaths they have caused.
    [Show full text]
  • Ensuring Adequate Access for Medical and Scientific Purposes
    INTERNATIONAL NARCOTICS CONTROL BOARD Availability of Internationally Controlled Drugs Controlled Internationally of Availability Availability of Internationally Controlled Drugs: Ensuring Adequate Access for Medical and Scientific Purposes Indispensable, adequately available and not unduly restricted UNITED NATIONS Reports published by the International Narcotics Control Board in 2015 TheReport of the International Narcotics Control Board for 2015 (E/INCB/2015/1) is supple- mented by the following reports: Availability of Internationally Controlled Drugs: Ensuring Adequate Access for Medical and Scientific Purposes. Indispensable, adequately available and not unduly restricted (E/INCB/2015/1/Supp.1) Narcotic Drugs: Estimated World Requirements for 2016—Statistics for 2014 (E/INCB/2015/2) Psychotropic Substances: Statistics for 2014—Assessments of Annual Medical and Scientific Requirements for Substances in Schedules II, III and IV of the Convention on Psychotropic Substances of 1971 (E/INCB/2015/3) Precursors and Chemicals Frequently Used in the Illicit Manufacture of Narcotic Drugs and Psychotropic Substances: Report of the International Narcotics Control Board for 2014 on the Implementation of Article 12 of the United Nations Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Substances of 1988 (E/INCB/2015/4) The updated lists of substances under international control, comprising narcotic drugs, psychotropic substances and substances frequently used in the illicit manufacture of narcotic drugs and psychotropic substances, are contained in the latest editions of the annexes to the statistical forms (“Yellow List”, “Green List” and “Red List”), which are also issued by the Board. Contacting the International Narcotics Control Board The secretariat of the Board may be reached at the following address: Vienna International Centre Room E-1339 P.O.
    [Show full text]
  • ESTIMATED WORLD REQUIREMENTS of NARCOTIC DRUGS in GRAMS for 2013 (January Update)
    ESTIMATED WORLD REQUIREMENTS OF NARCOTIC DRUGS IN GRAMS FOR 2013 (January update) Afghanistan Oxycodone 43 000 Codeine 50 000 Oxymorphone 300 Dextropropoxyphene 2 000 000 Pethidine 65 000 Diphenoxylate 20 000 Remifentanil 9 100 Fentanyl 6 Sufentanil 1 Methadone 6 000 Thebaine 45 000 Morphine 4 000 Armenia Pethidine 80 000 Codeine 3 000 Pholcodine 100 000 Fentanyl 21 Albania Methadone 10 000 Codeine 35 000 Morphine 4 500 Fentanyl 40 Thebaine 10 Methadone 9 000 Trimeperidine 650 Morphine 3 000 Aruba* Pethidine 2 500 Alfentanil 3 Pholcodine 1 000 Bezitramide 1 Remifentanil 8 Cocaine 70 Sufentanil 1 Codeine 85 Algeria Dextromoramide 1 Alfentanil 500 Dextropropoxyphene 85 Codeine 1 000 000 Fentanyl 130 Etorphine 1 Hydrocodone 2 Fentanyl 1 000 Methadone 150 Morphine 11 000 Morphine 340 Pethidine 3 000 Opium 450 Pholcodine 2 500 000 Oxycodone 26 Sufentanil 30 Pethidine 404 Andorra Piritramide 20 Fentanyl 80 Remifentanil 19 Methadone 1 000 Ascension Island Morphine 500 Alfentanil 1 Oxycodone 1 500 Fentanyl 1 Pethidine 500 Morphine 2 Remifentanil 4 Pethidine 9 Angola* Australia Alfentanil 2 Alfentanil 400 Codeine 30 000 Cannabis 21 500 Dextromoramide 375 Cocaine 20 000 Dihydrocodeine 375 Codeine 9 800 000 Fentanyl 45 Conc. of poppy straw Morphine 11 000 AOA 4 000 000 Pethidine 13 000 ATA 85 000 000 Sufentanil 2 Dextromoramide 10 Anguilla Dextropropoxyphene 1 925 000 Fentanyl 1 Difenoxin 7 Morphine 20 Dihydrocodeine 285 000 Pethidine 300 Diphenoxylate 80 000 Antigua and Barbuda* Ethylmorphine 10 Cocaine 9 Etorphine 2 Codeine 169 Fentanyl 40 000
    [Show full text]
  • FDA Briefing Document Joint Meeting of the Drug Safety and Risk Management (Dsarm) Advisory Committee and Anesthetic and Analges
    FDA Briefing Document Joint Meeting of the Drug Safety and Risk Management (DSaRM) Advisory Committee and Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC) June 11-12, 2019 1 The attached package contains background information prepared by the Food and Drug Administration (FDA) for the panel members of the advisory committee. The FDA background package often contains assessments and/or conclusions and recommendations written by individual FDA reviewers. Such conclusions and recommendations do not necessarily represent the final position of the individual reviewers, nor do they necessarily represent the final position of the Review Division or Office. We have brought the clinical utility and safety concerns associated with the higher range of opioid analgesic dosing (both in terms of higher strength products and higher daily doses) in the outpatient setting, to this Advisory Committee in order to gain the Committee’s insights and opinions, and the background package may not include all issues relevant to the final regulatory recommendation and instead is intended to focus on issues identified by the Agency for discussion by the advisory committee. The FDA will not issue a final determination on the issues at hand until input from the advisory committee process has been considered and all reviews have been finalized. The final determination may be affected by issues not discussed at the advisory committee meeting. 2 Table of Contents Page Office Director Memorandum 4 Division of Anesthesia, Analgesia, and Addiction Products (DAAAP) Memorandum: Opioids Regulatory Background 9 Division of Epidemiology (DEPI) Review: Prescribing Patterns, Clinical Use, and Risks Associated with Higher Dosage Strength Products and Higher Daily Dosing of Opioid Analgesics 29 3 OFFICE DIRECTOR MEMORANDUM Department of Health and Human Services Public Health Service Food and Drug Administration (FDA) Center for Drug Evaluation and Research (CDER) Office of Surveillance and Epidemiology (OSE) Date: May 22, 2019 From: Judy Staffa, Ph.D., R.Ph.
    [Show full text]